Latest Bioscience News

CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department GraduationMATTHEWS, N.C., May 25, 2012 /PRNewswire/ -- CEM Corporation president and CEO Michael J. Collins delivered the commencement address for the University of Texas at Austin Chemistry and Biochemistry Department, which was held on May 18, 2012. Collins received his PhD in Physical Chemistry from the University and has been a member of the Advisory Board for the Chemistry Department at the school...

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patentAlnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use...

Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory BoardCRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its n...

BBSRC allocates £250M for strategic investment programmesMinister for Universities and Science, David Willetts, will today announce substantial funding that will ensure the UK's bioscience research base remains globally competitive and at the forefront of meeting the grand challenges faced by society in th...

Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent AllowancesSAN DIEGO, May 25, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for the Company's platform NexACT® drug delivery technology. Specifically, the patent covers the synthe...

New Chronic Wound Therapy Awarded at Texas' Largest Life Science EventSAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies. Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capita...

Blueprint Medicines Welcomes Fidelity Biosciences to Investor SyndicateBlueprint Medicines today announced that new investor Fidelity Biosciences joined existing founding investor Third Rock Ventures in its previously announced $40 million Series A financing. “Blueprint has recruited exceptional talent and created an organization with a real opportunity to transform cancer dr

Alnylam, PBL sign licensing agreement for Baulcombe & Hamilton RNAi patentAlnylam Pharmaceuticals and Plant Bioscience (PBL) have entered into a licensing agreement for Baulcombe & Hamilton RNAi patent.

Alnylam secures rights to Plant Bioscience's RNAi patentPlant Bioscience granted Alnylam Pharmaceuticals global, non-exclusive licensing rights to the patent for Baulcombe and Hamil -More-

First bedside DNA test to be introduced in Middle EastSpartan Bioscience announces DELTA as exclusive distributor for Middle East Ottawa, Ontario (PRWEB) May 24, 2012 Spartan Bioscience today announced exclusive agreements with DELTA Trading & Development for distribution of the first bedside DNA test in the Middle East. The agreements cover Bahrain, Egypt, Kuwait, Oman, Qatar, Saudi Arabia, Sudan, and United Arab Emirates. DELTA specializes in...

U.K. providing $395.7M for bioscience researchThe U.K.'s Biotechnology and Biological Sciences Research Council awarded L250 million ($395.7 million) across eight institutes to fund bioscience research, including studies in healthcare, agriculture and energy. Institutes receiving funds for healt...

Blockbuster NYC & Tri-State Healthcare Real Estate Conference -- June 12NEW YORK, May 23, 2012 /PRNewswire/ -- More than 250 are expected to attend Healthcare & Real Estate 2012, a high-level informational and networking conference for healthcare investors, owners, operators, capital sources and service providers. The conference, which will be held at New York City's Scholastic Building, will feature Cushman & Wakefield's Scott A. Mason, recently ap...

Minister announces £250M strategic investment in UK bioscience(Biotechnology and Biological Sciences Research Council) Minister for Universities and Science, David Willetts, will today announce substantial funding that will ensure the UK's bioscience research base remains globally competitive and at the forefro...

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi PatentAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Plant Bioscience Limited (PBL), a technology development and intellectual property (IP) management company, announced today that they have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license

Selexis SA and Fusion Antibodies Services Form Partnership to Speed Therapeutic Monoclonal Antibody DevelopmentCustomers will be able to seamlessly go from non-human MAbs to clinical candidate generated in a cGMP ready CHO cell line in 8 months. Clinical candidates are selected based on both expression and binding activity from stable CHO pools. Geneva, Switzerland (PRWEB) May 23, 2012 Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of th...

IntelliCell signs stem cell, tissue repair research deal with University of FloridaIntelliCell BioSciences has signed a stem cell and tissue repair research agreement with the Institute for Cell Engineering and Regenerative Medicine at the University of Florida.

IntelliCell enters sponsored research agreement with ICERMIntelliCell BioSciences, Inc. announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida.

Insception Biosciences Inc. Proudly Announces FACT Accreditation TORONTO, ONTARIO -- (Marketwire) -- 05/23/12 -- Insception Cord Blood Program is proud to announce the achievement of FACT accreditation by demonstrating compliance with the NETCORD-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release. "Our commitment to the highest quality standards is demonstrated by achieving the voluntary FACT accreditat...

Ventria Bioscience to Participate in Business Partnering Program at 2012 BIO International ConventionFORT COLLINS, Colo. – May 23, 2012 – Company representatives from Ventria Bioscience will attend the 2012 BIO International Convention June 18 – 21 at the Boston Convention & Exhibition Center (Boston, Mass.). As in past years,...

GeneLink Reports First Quarter 2012 Financial ResultsORLANDO, Fla., May 22, 2012 /PRNewswire/ -- GeneLink, Inc. (OTCBB: GNLK.OB, "the Company," or "GeneLink"), a leading consumer genomics biotech company, reports financial results for the three months ended March 31, 2012. Financial Results: On February 10, 2012 the Company closed on the sale of its direct selling subsidiary, GeneWize Life Sciences, Inc., consummating a transaction entered i...

IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair ResearchNEW YORK, May 22, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK) announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida. A portion of the collaborative work will be to explore the physiological characteristics o...

May 22 is Gout Awareness Day: New gout recommendations highlight lifestyle changes as a key to managing acute gout symptomsPITTSBURGH, May 22, 2012 /PRNewswire/ -- New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine[1], highlight updated management recommendations for patients with acute gout. These new recommendations come at a time when the incidence of gout is soaring; 8.3 million Americans are estimated to be gout patients[2]. To view the multi...

AMO chief to retire; successor namedAbbott Medical Optics (AMO) has announced an impending change in leadership with the expected retirement of James V. Mazzo, president and chief executive officer (CEO), by the end of this year. Mazzo will be succeeded by Murthy Simhambhatla,...

Apricus Biosciences Granted Regulatory Guidance With FDA for MycoVa(TM) for the Treatment of OnychomycosisSAN DIEGO, May 22, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the United States ("U.S.") Food and Drug Administration ("FDA") has granted the Company's request for Type C regulatory guidance from the agency for MycoVa™, the Company's topical treatment for onychomycosis, or nail fungus. The gu...

Senate Begins Debate on FDA User Fee Bill with Bennet ProvisionsIncludes Bennet Measures to Improve Drug Safety, Bring Breakthrough Treatments to Patients Quicker, Advance Medical Device Innovation and Avoid Critical Drug Shortages Washington, DC – The U.S. Senate today began debate on a bipartisan bill to...

0 1 2 3 4 ›»

buy Bioscience market research data and corporate reports now Advertisement